Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000039168 | SCV000062852 | uncertain significance | not specified | 2016-06-02 | criteria provided, single submitter | clinical testing | The p.Gly1329Asp variant in CDH23 has been previously reported in the heterozygo us state in 1 individual with hearing loss by our laboratory and in 1 individual with Usher syndrome (Bujakowska 2014). However, neither individual had a second variant affecting the remaining copy of CDH23 and the individual reported by Bu jakowska (2014) had an alternate explanation of the hearing loss identified. Thi s variant was also identified in 35/63866 European chromosomes by the Exome Aggr egation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs201877610). Al though this variant has been seen in the general population, its frequency is no t high enough to rule out a pathogenic role. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though t his information is not predictive enough to determine pathogenicity. In summar y, the clinical significance of the p.Gly1329Asp variant is uncertain. |
Gene |
RCV000726811 | SCV000577393 | uncertain significance | not provided | 2023-02-10 | criteria provided, single submitter | clinical testing | Observed in an individual with Usher syndrome type 1 in published literature who had a different genetic etiology for the phenotype (Bujakowska et al., 2014); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24875298, 25468891) |
Eurofins Ntd Llc |
RCV000726811 | SCV000703221 | uncertain significance | not provided | 2016-11-10 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000764916 | SCV000896079 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 12; Usher syndrome type 1D; Pituitary adenoma 5, multiple types | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001105664 | SCV001262649 | uncertain significance | Usher syndrome type 1D | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Illumina Laboratory Services, |
RCV001105665 | SCV001262650 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 12 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Invitae | RCV000726811 | SCV001419962 | uncertain significance | not provided | 2022-10-25 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 1329 of the CDH23 protein (p.Gly1329Asp). This variant is present in population databases (rs201877610, gnomAD 0.06%). This variant has not been reported in the literature in individuals affected with CDH23-related conditions. ClinVar contains an entry for this variant (Variation ID: 45934). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on CDH23 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001831663 | SCV002090678 | uncertain significance | Usher syndrome type 1 | 2020-02-14 | no assertion criteria provided | clinical testing |